Search results
In June 2009, Feuerstein alleged the company was "seeking to divert investors' attention away from the delayed approval of Ampligen as a treatment for chronic fatigue syndrome" by issuing three press releases in seven days about research from 2007 into possible applications for Ampligen as a flu vaccine booster, in which Hemispherx stated that ...
Rintatolimod (tradename Ampligen ®) is a mismatched, double-stranded RNA molecule with immunomodulatory and antiviral properties. The drug acts as a TLR3 agonist which stimulates the production of interferons and tumor necrosis factors. It is manufactured by AIM ImmunoTech, formerly known as Hemispherx Biopharma. [1]
Ampligen is the only known TLR3 agonist to avoid helicase activation of NF-κB. Natural dsRNAs and poly IC which activate NF-κB in the tumor microenvironment (TME) ↑Tregs and have the potential to enhance cancer cell proliferation (Theodoraki, et al. 2018) Kalinski Unpub. Data .
A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ampligen® in Patients With Post-COVID Conditions Secondary IDs: Study Status
9 lut 2015 · Ampligen (rintatolimod) is a new drug in development for the treatment of a variety of chronic diseases and viral disorders. Ampligen information includes news, clinical trial results and side effects.
In October 2020, AIM received Institutional Review Board approval for the expansion of the AMP-511 protocol to include patients previously diagnosed with SARS-CoV-2 following clearance of the virus, but who still demonstrate chronic fatigue-like symptoms (Long COVID).
14 mar 2012 · All patients gave written informed consent and had a diagnosis of CFS ≥12 months resulting in significant debilitation (KPS score of 40–60). A list of Principal Investigators in the CFS AMP-516 Study Group is shown in Table S2 along with the 12 study sites and Institutional Review Boards.
